Form 4: Cytokinetics Insider Trades: CEO Sells Shares

Cytokinetics CEO Robert I. Blum reported a sale of 7,500 shares of common stock on July 1, 2026, for $84.92 per share.

Summary

• Robert I. Blum, President & CEO and Director of Cytokinetics Inc. (CYTK), reported a transaction on July 1, 2026.
• Blum sold 7,500 shares of common stock at a price of $84.92 per share.
• Following this transaction, Blum directly beneficially owns 377,830 shares.
• Additionally, Blum indirectly beneficially owns 2,083 shares through The Bridget Blum 2003 Irrevocable Trust and 2,083 shares through The Brittany Blum 2003 Irrevocable Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing neutrally as it reports a standard insider transaction without providing performance or strategic information.

Negatives

• Insider selling by the CEO can sometimes be perceived negatively by the market, although the reason for the sale is not specified.

Future Outlook

No forward-looking statements or guidance are present in this filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures of insider transactions. While this filing details a sale by the CEO, it does not provide insight into the company's operational performance or future prospects, which would be found in other SEC filings like 10-Q or 10-K.

Stakeholder Impact

• Shareholders: The sale of shares by the CEO may lead to questions about the CEO's confidence in the company's future performance, though the specific reasons for the sale are not disclosed.

Key Dates

Keywords

Cytokinetics, CYTK, Form 4, Insider Trading, Stock Sale, CEO, Beneficial Ownership, Common Stock